MY155652A - Improvements in or relating to compositions - Google Patents

Improvements in or relating to compositions

Info

Publication number
MY155652A
MY155652A MYPI2011000776A MYPI20110776A MY155652A MY 155652 A MY155652 A MY 155652A MY PI2011000776 A MYPI2011000776 A MY PI2011000776A MY PI20110776 A MYPI20110776 A MY PI20110776A MY 155652 A MY155652 A MY 155652A
Authority
MY
Malaysia
Prior art keywords
compositions
relating
hexitidine
amylmetacresol
hexylresorcinol
Prior art date
Application number
MYPI2011000776A
Other languages
English (en)
Inventor
Campbell Alistair
Original Assignee
Reckitt Benckiser Healthcare
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0815405A external-priority patent/GB0815405D0/en
Priority claimed from GB0900288A external-priority patent/GB0900288D0/en
Application filed by Reckitt Benckiser Healthcare filed Critical Reckitt Benckiser Healthcare
Publication of MY155652A publication Critical patent/MY155652A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
    • A61J1/035—Blister-type containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MYPI2011000776A 2008-08-22 2009-08-18 Improvements in or relating to compositions MY155652A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0815405A GB0815405D0 (en) 2008-08-22 2008-08-22 Novel compositions
GB0900288A GB0900288D0 (en) 2009-01-09 2009-01-09 Novel compositions

Publications (1)

Publication Number Publication Date
MY155652A true MY155652A (en) 2015-11-13

Family

ID=41343399

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2011000776A MY155652A (en) 2008-08-22 2009-08-18 Improvements in or relating to compositions

Country Status (14)

Country Link
US (2) US8569375B2 (enExample)
EP (1) EP2328549B1 (enExample)
JP (1) JP2012500786A (enExample)
KR (1) KR20110056500A (enExample)
CN (1) CN102131496B (enExample)
AU (1) AU2009284011B2 (enExample)
BR (1) BRPI0917191A2 (enExample)
CA (1) CA2733180A1 (enExample)
MX (1) MX344359B (enExample)
MY (1) MY155652A (enExample)
RU (1) RU2493829C2 (enExample)
TW (1) TW201010744A (enExample)
WO (1) WO2010020772A2 (enExample)
ZA (1) ZA201100960B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10092524B2 (en) 2008-06-11 2018-10-09 Edge Therapeutics, Inc. Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage
CN102131496B (zh) * 2008-08-22 2013-10-23 雷克特本克斯尔保健(英国)有限公司 组合物的改进或与组合物有关的改进
US20120283668A1 (en) * 2011-05-04 2012-11-08 Pinchas Shalev Apparatus and method for using effervescent tablets for cosmetic care
US20130284637A1 (en) 2012-04-30 2013-10-31 Danisco Us Inc. Unit-dose format perhydrolase systems
KR20150100705A (ko) * 2013-04-18 2015-09-02 더 허쉬 컴퍼니 미분 점활제를 함유하는 식용물질
WO2016126217A1 (en) * 2015-02-03 2016-08-11 Pharmacti̇ve Ilaç Sanayi̇ Ve Ti̇caret A. Ş. Stable pharmaceutical combination containing benzydamine
CA3050738A1 (en) * 2017-02-01 2018-08-09 Johnson & Johnson Consumer Inc. A lozenge
AU2018300075B2 (en) * 2017-07-10 2024-02-29 Gel Cap Technologies, LLC Dual release dosage form capsule and methods, devices and systems for making same
WO2020013781A2 (en) 2018-03-27 2020-01-16 Pisak Mehmet Nevzat Synergistic effect of flurbiprofen and a gastro protective agent for the treatment of pain and inflammation
CN110812331A (zh) * 2018-08-10 2020-02-21 北京普德康利医药科技发展有限公司 一种氟比洛芬咽部滞留颗粒
WO2022005932A1 (en) * 2020-06-30 2022-01-06 Glaxosmithkline Consumer Healthcare Holdings (Us) Llc Lozenge
RU2741388C1 (ru) * 2020-08-06 2021-01-25 Закрытое акционерное общество "АФОФАРМ" (ЗАО "АФОФАРМ") Лекарственный препарат в форме таблеток для профилактики и/или лечения простудных, острых респираторных и других инфекционно-воспалительных заболеваний горла и полости рта

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6216413A (ja) * 1985-07-12 1987-01-24 Teijin Ltd キチン類誘導体を用いた徐放性医薬品組成物
US5458879A (en) * 1994-03-03 1995-10-17 The Procter & Gamble Company Oral vehicle compositions
AU4988696A (en) * 1995-03-29 1996-10-16 Procter & Gamble Company, The Antitussive microcapsules
KR100598714B1 (ko) * 1995-12-21 2006-07-10 파마슈티스크 라보라토리움 페링 에이/에스 5-아미노살리실산을 함유하는 방출 제어형 경구용 약제학적조성물 및 장 질환을 치료하는 방법
IT1297233B1 (it) * 1996-10-29 1999-08-09 Montefarmaco Spa Composizioni farmaceutiche solide in forma di caramelle contenenti disinfettanti e sostanze mucoadesive per una disinfezione topica
GB9710521D0 (en) * 1997-05-22 1997-07-16 Boots Co Plc Process
WO2000035418A2 (en) * 1998-12-18 2000-06-22 Bayer Corporation Chewable drug delivery system
US6183779B1 (en) * 1999-03-22 2001-02-06 Pharmascience Inc. Stabilized pharmaceutical composition of a nonsteroidal anti-inflammatory agent and a prostaglandin
JP2003002828A (ja) * 2001-04-17 2003-01-08 Tanabe Seiyaku Co Ltd 口腔粘膜等における炎症性疾患の予防・治療剤
GB0113843D0 (en) * 2001-06-07 2001-08-01 Boots Co Plc Therapeutic agents
JP4754211B2 (ja) * 2004-12-28 2011-08-24 ライオン株式会社 粒状医薬組成物及びその製造方法
GB0515492D0 (en) * 2005-07-28 2005-08-31 Reckitt Benckiser Healthcare Improvements in or relating to compositions,articles and methods
EP2015761A4 (en) * 2006-03-29 2009-07-29 Naveh Pharma 1996 Ltd METHOD AND COMPOSITION FOR THE TREATMENT OF NUTRITIONAL IGNITION
JP2007314529A (ja) * 2006-04-28 2007-12-06 Lion Corp 造粒粒子、錠剤、及び造粒粒子の製造方法
US7754234B2 (en) * 2006-07-12 2010-07-13 Jones Thomas L Composition and method of treating a sore throat
CN102131496B (zh) * 2008-08-22 2013-10-23 雷克特本克斯尔保健(英国)有限公司 组合物的改进或与组合物有关的改进

Also Published As

Publication number Publication date
CA2733180A1 (en) 2010-02-25
BRPI0917191A2 (pt) 2015-11-10
ZA201100960B (en) 2012-04-25
AU2009284011B2 (en) 2013-12-12
CN102131496B (zh) 2013-10-23
US20110201685A1 (en) 2011-08-18
EP2328549B1 (en) 2017-11-15
EP2328549A2 (en) 2011-06-08
US20140039057A1 (en) 2014-02-06
KR20110056500A (ko) 2011-05-30
MX2011001950A (es) 2011-04-04
TW201010744A (en) 2010-03-16
RU2493829C2 (ru) 2013-09-27
AU2009284011A1 (en) 2010-02-25
RU2011110715A (ru) 2012-09-27
WO2010020772A3 (en) 2010-07-15
JP2012500786A (ja) 2012-01-12
WO2010020772A2 (en) 2010-02-25
MX344359B (es) 2016-12-14
US8569375B2 (en) 2013-10-29
CN102131496A (zh) 2011-07-20

Similar Documents

Publication Publication Date Title
MY155652A (en) Improvements in or relating to compositions
JP2012500786A5 (enExample)
NO20073559L (no) Nanopartiklulaere tacrolimus-formuleringer
WO2008008617A3 (en) Methods of making compositions comprising films
PE20081459A1 (es) 4-[4-({[4-cloro-3-(triflourometil)fenil]carbamoil}amino)-3-fluorofenoxi]-n-metilpiridin-2-carboxamida monohidratada
CA2816977A1 (en) Compositions and methods relating to reduced mucoadhesion
WO2010090855A3 (en) Oral care composition to reduce or eliminate dental sensitivity
JP2010515761A5 (enExample)
MX2012004932A (es) Composiciones orales para el tratamiento de la boca seca.
TR201906970T4 (tr) Fenilefrin ihtiva eden sıvı formülasyonlar.
NZ600640A (en) Abuse-resistant formulations
GB0614353D0 (en) Oral compositions, their preparation and use
MA34286B1 (fr) Compositions pharmaceutiques et procédés pour les fabriquer
MX2013007237A (es) Peliculas y composiciones que comprenden las mismas.
WO2007062995A3 (en) Glucan compositions
WO2012001074A3 (en) Pharmaceutical compositions comprising 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactate monohydrate
ATE520406T1 (de) Kristalline form des ibandronat-natriums
MY157790A (en) Trazodone composition for once a day administration
DE602006011288D1 (de) Mentholhaltige feststoffzusammensetzung
WO2008122578A3 (en) Oral care composition comprising particulate zinc oxide
WO2008067436A3 (en) Compounds and formulations suitable for radical scavenging
WO2011056759A3 (en) Oral compositions for treatment of dry mouth
JP2010100583A5 (enExample)
MX2008001317A (es) Composiciones en forma de particulas que comprenden alginato y/o acido alginico.
JP2011508779A5 (enExample)